

## HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT WITH THE BROKERAGE FIRM KEPLER CHEUVREUX

**Paris, France, July 18, 2024 – 6:00 pm CEST –** ACTICOR BIOTECH (ISIN: FR00140050J5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30<sup>th</sup>, 2024:

- 245,176 shares
- € 252,168.60
- Number of executions on buy side on semester: 990
- Number of executions on sell side on semester: 956
- Traded volume on buy side on semester: 504,480 shares for € 524,812.30
- Traded volume on sell side on semester: 324,426 shares for € 473,133.44

As a reminder:

- the following resources appeared on the last half year statement on 31 December 2023 on the liquidity account:
  - 65,122 shares
  - € 299,098.61
  - Number of executions on buy side on semester: 340
  - Number of executions on sell side on semester: 227
  - Traded volume on buy side on semester: 39,590 shares for € 173,764.12
  - Traded volume on sell side on semester: 17,891 shares for € 85,132.33
  
- the following resources appeared on the liquidity account when the activity started:
  - 0 shares
  - € 600,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

### About ACTICOR BIOTECH

Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, particularly ischemic stroke.

The positive results of the phase 1b/2a study, ACTIMIS, published in January 2024 in the Lancet Neurology ([link to publication](#)) confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. A post-hoc analysis of brain imaging at 0 and 24 hours using artificial intelligence confirmed these results, showing a reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab.

On April 25, 2024, the company announced the initial results of the international phase 2/3 ACTISAVE study in the treatment of acute ischemic stroke, which showed no efficacy of glenzocimab on the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) 90 days after stroke, nor on the secondary endpoint, the proportion of patients returning to life without disability (mRS 0-2).

On May 15, 2024, Prof. Martin Köhrmann (Principal Investigator of ACTISAVE) presented the main results of the study at the opening session of the European Stroke Organization Conference (ESOC), confirming the neutrality of the study on the primary and secondary endpoints, and showing trends in return to normal life (mRS 0-1), notably in sub-populations of patients with complete recanalization after mechanical thrombectomy.

Glenzocimab is being evaluated in 2 other clinical trials initiated by academic teams:

- GREEN: a phase 2/3 study in the treatment of stroke in thrombectomized patients, with a futility analysis after inclusion of the first 78 patients (30% of patients) expected in Q4 2024;
- LIBERATE: a Phase 2b LIBERATE trial in the treatment of myocardial infarction, with final results expected in Q4 2025.

Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR00140050J5 - ALACT).

For more information, visit: [www.acticor-biotech.com](http://www.acticor-biotech.com)

---

## Contacts

### **ACTICOR BIOTECH**

Gilles AVENARD, MD

CEO and Founder

[gilles.avenard@acticor-biotech.com](mailto:gilles.avenard@acticor-biotech.com)

T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD

General Manager and CSO

[Sophie.binay@acticor-biotech.com](mailto:Sophie.binay@acticor-biotech.com)

T. : +33 (0)6 76 23 38 13

### **NewCap**

Mathilde BOHIN

Investor Relations

[acticor@newcap.eu](mailto:acticor@newcap.eu)

T. : +33 (0)1 44 71 94 95

### **NewCap**

Arthur ROUILLÉ

Media Relations

[acticor@newcap.eu](mailto:acticor@newcap.eu)

T. : +33 (0)1 44 71 00 15

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>990</b>	<b>504,480</b>	<b>524,812.30</b>	<b>956</b>	<b>324,426</b>	<b>473,133.44</b>
02/01/2024	1	250	725.00	2	250	737.50
05/01/2024	3	251	740.45	1	1	2.97
08/01/2024	-	-	-	8	750	2,257.50
09/01/2024	-	-	-	5	675	2,112.75
10/01/2024	1	100	306.00	3	25	79.00
11/01/2024	6	901	2,703.00	3	251	778.10
12/01/2024	6	1,223	3,510.01	4	501	1,477.95
15/01/2024	5	500	1,435.00	4	159	457.92
16/01/2024	2	250	710.00	4	108	312.12
17/01/2024	5	500	1,420.00	1	83	237.38
18/01/2024	1	1	2.84	3	501	1,437.87
19/01/2024	3	188	537.68	4	250	725.00
22/01/2024	-	-	-	4	750	2,227.50
23/01/2024	-	-	-	36	6,500	28,535.00
24/01/2024	-	-	-	38	5,726	30,004.24
25/01/2024	17	2,000	8,960.00	8	994	4,622.10
26/01/2024	6	750	3,232.50	3	402	1,776.84
29/01/2024	8	750	3,285.00	7	604	2,742.16
30/01/2024	4	463	2,046.46	3	750	3,367.50
31/01/2024	6	1,037	4,490.21	2	500	2,190.00
01/02/2024	12	1,000	4,260.00	-	-	-
02/02/2024	6	750	3,157.50	2	250	1,090.00
05/02/2024	7	500	2,100.00	5	501	2,134.26
06/02/2024	7	660	2,831.40	4	500	2,200.00
07/02/2024	5	395	1,666.90	3	501	2,169.33
08/02/2024	10	1,274	5,287.10	9	815	3,423.00
09/02/2024	4	267	1,148.10	5	686	3,018.40
12/02/2024	3	503	2,213.20	2	497	2,211.65
13/02/2024	4	731	3,135.99	1	1	4.43
14/02/2024	5	850	3,638.00	3	376	1,650.64
15/02/2024	2	399	1,687.77	-	-	-
16/02/2024	1	250	1,075.00	13	2,123	9,426.12
19/02/2024	3	250	1,100.00	1	250	1,125.00

20/02/2024	6	950	4,284.50	6	1,250	5,700.00
21/02/2024	-	-	-	22	1,877	8,859.44
22/02/2024	-	-	-	14	1,623	8,098.77
23/02/2024	-	-	-	12	1,250	6,287.50
26/02/2024	8	1,250	6,075.00	2	456	2,252.64
27/02/2024	7	751	3,717.45	17	2,244	11,264.88
28/02/2024	3	500	2,510.00	25	2,001	10,145.07
29/02/2024	7	1,001	4,984.98	15	999	5,094.90
01/03/2024	4	1,000	5,020.00	21	3,274	16,992.06
04/03/2024	27	1,748	8,477.80	7	782	3,831.80
05/03/2024	1	5	24.70	15	2,718	13,617.18
06/03/2024	-	-	-	16	1,750	8,925.00
07/03/2024	8	831	4,188.24	3	144	740.16
08/03/2024	27	4,998	22,840.86	9	988	4,544.80
11/03/2024	10	1,940	8,749.40	8	689	3,128.06
12/03/2024	5	651	2,942.52	4	498	2,280.84
13/03/2024	6	950	4,294.00	5	514	2,343.84
14/03/2024	13	2,576	11,257.12	8	702	3,130.92
15/03/2024	28	4,721	15,248.83	-	-	-
18/03/2024	11	2,500	8,250.00	-	-	-
19/03/2024	15	3,100	9,486.00	-	-	-
20/03/2024	11	2,750	7,975.00	-	-	-
21/03/2024	8	1,272	3,739.68	-	-	-
22/03/2024	10	1,978	5,657.08	-	-	-
25/03/2024	7	410	1,271.00	-	-	-
26/03/2024	3	97	300.70	-	-	-
27/03/2024	3	252	806.40	-	-	-
28/03/2024	2	498	1,628.46	-	-	-
02/04/2024	2	500	1,635.00	-	-	-
03/04/2024	2	500	1,610.00	-	-	-
04/04/2024	1	36	118.80	-	-	-
05/04/2024	1	250	835.00	-	-	-
08/04/2024	2	250	850.00	-	-	-
09/04/2024	1	250	850.00	-	-	-
10/04/2024	3	110	374.00	-	-	-
11/04/2024	2	390	1,337.70	-	-	-
12/04/2024	4	500	1,800.00	-	-	-
15/04/2024	3	456	1,673.52	-	-	-
16/04/2024	7	664	2,529.84	2	500	1,965.00
17/04/2024	3	250	975.00	3	699	2,775.03

18/04/2024	1	46	185.84	4	301	1,219.05
19/04/2024	-	-	-	9	1,318	5,496.06
22/04/2024	21	6,943	26,730.55	17	2,250	8,775.00
23/04/2024	3	199	754.21	6	750	2,887.50
24/04/2024	9	2,048	7,864.32	11	2,250	9,022.50
25/04/2024	17	45,000	13,950.00	-	-	-
26/04/2024	53	110,000	42,900.00	-	-	-
29/04/2024	14	6,518	2,542.02	7	5,000	2,100.00
30/04/2024	23	17,982	6,653.34	10	4,000	1,560.00
02/05/2024	21	16,355	6,214.90	7	6,000	2,520.00
03/05/2024	1	1,000	390.00	1	1,000	400.00
06/05/2024	1	1,000	400.00	4	4,000	1,680.00
07/05/2024	5	4,000	2,000.00	48	32,792	17,051.84
08/05/2024	5	4,000	2,840.00	74	44,208	32,713.92
09/05/2024	59	24,740	20,039.40	31	14,412	12,394.32
10/05/2024	16	11,900	7,735.00	34	21,180	16,308.60
13/05/2024	22	11,700	8,892.00	14	8,000	6,320.00
14/05/2024	8	6,000	4,620.00	25	13,000	10,530.00
15/05/2024	-	-	-	47	27,593	28,420.79
16/05/2024	30	16,406	15,913.82	18	11,000	11,550.00
17/05/2024	7	7,000	6,650.00	5	1,227	1,202.46
20/05/2024	19	10,094	9,387.42	9	3,984	3,784.80
21/05/2024	17	9,700	8,827.00	9	4,625	4,301.25
22/05/2024	9	5,000	4,550.00	7	2,274	2,092.08
23/05/2024	6	5,000	4,350.00	1	25	22.75
24/05/2024	11	4,004	3,323.32	-	-	-
27/05/2024	12	5,996	4,916.72	-	-	-
28/05/2024	10	6,000	4,680.00	-	-	-
29/05/2024	10	3,428	2,639.56	4	3,000	2,370.00
30/05/2024	21	13,952	10,045.44	-	-	-
31/05/2024	8	4,620	3,095.40	-	-	-
03/06/2024	-	-	-	10	4,000	3,240.00
04/06/2024	-	-	-	41	24,165	23,681.70
05/06/2024	-	-	-	7	4,915	5,603.10
06/06/2024	11	8,000	7,520.00	2	165	181.50
07/06/2024	2	1,000	920.00	-	-	-
10/06/2024	13	10,000	8,600.00	6	1,000	880.00
11/06/2024	9	4,500	3,780.00	-	-	-
12/06/2024	7	4,001	3,280.82	4	3,001	2,520.84
13/06/2024	18	7,866	6,371.46	1	424	360.40

14/06/2024	27	22,134	15,493.80	31	4,587	3,256.77
17/06/2024	13	9,969	6,778.92	13	5,543	4,046.39
18/06/2024	-	-	-	16	4,300	3,010.00
19/06/2024	7	1,774	1,224.06	-	-	-
20/06/2024	5	1,226	858.20	8	4,800	3,552.00
24/06/2024	2	500	380.00	2	770	592.90
25/06/2024	12	5,000	3,700.00	5	398	302.48
26/06/2024	11	4,019	2,893.68	2	930	669.60
27/06/2024	3	1,001	710.71	1	1	0.72
28/06/2024	7	4,981	3,486.70	-	-	-